Clinical trials: HBP
Hypertension
Candesartan Cilexetil/Amlodipine Besilate Combination Tablets LD, HD Special Drug Use Surveillance "Hypertension: Long-Term Use"
The purpose of this survey is to investigate the safety and efficacy of long-term use of candesartan cilexetil/amlodipine besilate combination tablets (Unisia Combination Tablets) low dose (LD), high dose (HD) in participants…
- Trial name
- NCT02068495
- Testing
- Candesartan cilexetil/Amlodipine besilate
- Volunteers
- 3,409 people
- Sponsor
- Takeda
Hypertension
Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension
The purpose of the study is to test the efficacy and safety of the combination of Calcium Channel Blockers (CCBs)(of the dihydropyridine class) or Diuretics (of the thiazide class) and olmesartan medoxomil in essential…
- Trial name
- NCT00858702
- Testing
- olmesartan medoxomil and a CCB, olmesartan medoxomil and a diuretic
- Where
- Japan
- Volunteers
- 105 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Primary Open-angle Glaucoma, Cataract
MINIject Implantation Combined With Cataract Surgery in Patients With POAG and Cataract
The study will assess safety and performance of MINIject implant in patients with open-angle glaucoma uncontrolled by topical hypotensive medications in conjunction with cataract surgery.
- Trial name
- STAR-VI (NCT05432245)
- Testing
- Phacoemulsification combined with minimally invasive glaucoma surgery (MIGS)
- Where
- 4 sites in Panama, Spain and 1 more
- Volunteers
- 30 people
- Sponsor
- iSTAR Medical
Open Angle Glaucoma, Ocular Hypertension
Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan
Test ocular hypotensive efficacy and systemic safety of netarsudil 0.01%, 0.02%, 0.04% relative to placebo in subjects with open-angle glaucoma or ocular hypertension in Japan
- Trial name
- NCT03844945
- Testing
- Netarsudil Ophthalmic Solution 0.01%, Netarsudil Ophthalmic Solution 0.02%, Netarsudil Ophthalmic Solution 0.04%
- Where
- 25 sites in Japan
- Volunteers
- 215 people
- Sponsor
- Aerie Pharmaceuticals
Hypertension, Pulmonary
A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.
To provide riociguat therapy to eligible patients with PAH originating from Bayer-sponsored trials with BAY63-2521/ Riociguat / Adempas® who are currently or recently treated in these trials until lack of patient benefit as…
- Trial name
- RIALTO (NCT02759419)
- Testing
- Adempas (Riociguat, BAY63-2521)
- Where
- 9 sites in France, South Korea
- Volunteers
- 18 people
- Sponsor
- Bayer
Hypertension, Vascular Diseases
Renal Denervation in Patients With Uncontrolled Hypertension - SYMPLICITY HTN-4
An international, multi-center, prospective, blinded, randomized, controlled trial. The objective is to demonstrate that catheter-based renal denervation is an effective and safe treatment for uncontrolled hypertension.
- Conditions
- Hypertension, Vascular Diseases, Cardiovascular Diseases
- Trial name
- HTN-4 (NCT01972139)
- Testing
- Renal Denervation using the Symplicity Renal Denervation System, Renal Angiography
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Medtronic Vascular
Essential Hypertension, Primary Hypercholesterolemia
A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia
The objective of this clinical study is to evaluate the efficacy and safety by comparing BR1017A+BR1017B treatment group to BR1017A treatment group and BR1017B treatment group respectively at Week 8 in essential hypertension…
- Trial name
- NCT05930028
- Testing
- Fimasartan, Ezetimibe/Atorvastatin
- Where
- South Korea
- Volunteers
- 148 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Glaucoma, Open-Angle, Ocular Hypertension
A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma
To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12.
- Trial name
- NCT00159653
- Testing
- Xalacom, Xalatan, Timolol
- Where
- 55 sites in United States, Canada
- Volunteers
- 500 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension
Single and Multiple Ascending Doses Clinical Pharmacology Study With KAR5585
Safety, tolerability, pharmacokinetics (PK), cardiac conduction and food effect study on single and multiple ascending doses of KAR5585 in healthy adults.
- Trial name
- NCT02746237
- Testing
- KAR5585 Capsules
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Karos Pharmaceuticals
Hypertension, Pulmonary, Ventricular Dysfunction, Left
Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics
The aim of this study is to assess whether oral Riociguat affects the left ventricular contractility and relaxation in patients with pulmonary hypertension associated with left ventricular systolic dysfunction
- Trial name
- HEARTWORK (NCT01065051)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)
Researchers are looking for other ways to treat people with PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow to the lungs.
- Trial name
- LIGHTRAY (NCT06664801)
- Testing
- Sotatercept, Background PAH Therapy
- Where
- 98 sites in United States, Argentina and 19 more
- Volunteers
- 164 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH
The goal of this clinical trial is to evaluate safety and tolerability of preservative-free parenteral treprostinil in paediatric patients with PAH (PH Group 1) who are below 18 years of age.
- Trial name
- NCT06350032
- Testing
- preservative-free parenteral treprostinil
- Where
- 5 sites in Austria, France and 3 more
- Volunteers
- 20 people
- Sponsor
- AOP Orphan Pharmaceuticals AG
Open-Angle Glaucoma, Ocular Hypertension
Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study was to compare the intraocular pressure (IOP)-lowering efficacy and safety of AZARGA™ (Brinzolamide 1%/Timolol 0.5% Ophthalmic Suspension), dosed twice daily versus AZOPT® (Brinzolamide 1% Ophthalmic…
- Trial name
- NCT01357616
- Testing
- Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension, Brinzolamide 1% ophthalmic suspension, Timolol 0.5% ophthalmic solution
- Volunteers
- 328 people
- Sponsor
- Alcon Research
Essential Hypertension
Fimasartan/Amlodipine Combination Phase III
The aim of this study is to ensure the superiority of Fimasartan/Amlodipine combination in hypotensive effect after 8 weeks of treatment over Fimasartan monotherapy in patients with hypertension who have no response to Fimasartan…
- Trial name
- NCT02152306
- Testing
- Fimasartan and Amlodipine, Fimasartan
- Where
- South Korea
- Volunteers
- 143 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension Associated, Type II Diabetes Mellitus
Efficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and Hypertension
The purpose of this study is to evaluate the efficacy and safety of Egito association in the treatment of type 2 diabetes mellitus and hypertension
- Trial name
- EGITO (NCT04970108)
- Testing
- Egito, Empagliflozin + telmisartan
- Sponsor
- EMS
Hypertension
A Study Investigating the Bioequivalence of the Fixed Dose Combination of COREG CR to COREG CR and ZESTRIL.
This study will be a randomized study investigating the bioequivalence of COREG CR to its components, COREG and Lisinopril (ZESTRIL).
- Trial name
- NCT00552708
- Testing
- COREG CR, Lisinopril
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hypertension, Hyperlipidemias
Pharmacokinetic Drug-drug Interaction of CKD-330 and D086
The purpose of the study is examining and comparing the pharmacokinetic drug interaction and safety of both single administration and combination administration of CKD-330 and D086 to healthy male subjects
- Trial name
- NCT03017950
- Testing
- CKD-330, D086, CKD-330 + D086
- Where
- South Korea
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Glaucoma, Open-Angle, Ocular Hypertension
Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension
This study will evaluate the efficacy and safety of bimatoprost SR in participants with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.
- Trial name
- NCT02247804
- Testing
- Bimatoprost SR, Active Comparator: Timolol 0.5%
- Where
- 106 sites in United States, Australia and 12 more
- Volunteers
- 594 people
- Sponsor
- Allergan
Ocular Hypertension, Glaucoma
Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
The study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution in comparison with AGN-210669 vehicle and bimatoprost ophthalmic solution dosed once-daily each morning, in subjects with ocular hypertension or…
- Trial name
- NCT00809848
- Testing
- AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, AGN-210669 ophthalmic solution, 0.025%
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Allergan
Severe Hypertension
Study of CS-3150 in Patients With Severe Hypertension
To examine antihypertensive effect and safety of administration of CS-3150 in patients with severe hypertension (Grade III).
- Trial name
- NCT02808026
- Testing
- CS-3150
- Where
- Japan
- Volunteers
- 20 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.